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Enterobacteriaceae producing the OXA-48 carbapenemase are emerging worldwide, leaving few treatment options. Efﬁcacy
has been demonstrated in vivo with ceftazidime against a ceftazidime-susceptible OXA-48 isolate but not with imipenem
despite maintaining susceptibility. The relationship between phenotype and in vivo efﬁcacy was assessed for OXA-48
producers using humanized regimens of 2 g doripenem every 8 h (q8h; 4 h infusion), 1 g ertapenem q24h, 2 g ceftazidime
q8h (2 h inf), and 500 mg levoﬂoxacin q24h. Each regimen was evaluated over 24 h against an isogenic pair (wild-type and
OXA-48 Klebsiella pneumoniae strains) and six clinical OXA-48 isolates with and without other extended-spectrum -lactama-
ses in immunocompetent and neutropenic murine thigh infection models. Efﬁcacy was determined using the change in bacterial
density versus 24-h growth controls in immunocompetent studies and 0-h controls in neutropenic studies. Bacterial reductions
of>1 log CFU were observed with all agents for the wild-type strain. Consistent with low MICs, ceftazidime and levoﬂoxacin
exhibited efﬁcacy against the isogenic OXA-48 strain, whereas doripenem did not, despite having a susceptible MIC; no activity
was observed with ertapenem, consistent with a resistant MIC. Similar trends were observed for the clinical isolates evaluated.
Ceftazidime, levoﬂoxacin, and ertapenem efﬁcacy against isogenic and clinical OXA-48-producing strains correlated well with
phenotypic proﬁles and pharmacodynamic targets, whereas efﬁcacy with doripenem was variable over the MIC range studied.
These data suggest that carbapenems may not be a reliable treatment for treating OXA-48 producers and add to previous obser-
vations with KPC and NDM-1 suggesting that genotype may better predict activity of the carbapenems than the phenotypic
proﬁle.
Carbapenem resistance among the Enterobacteriaceae has beenon the rise worldwide over the last decade, commonly medi-
ated by Ambler class A -lactamases such as KPC, as well as Am-
bler class B metallo--lactamases, including VIM, IMP, and
NDM-1 (1). However, carbapenem resistance secondary to the
Ambler class D -lactamase OXA-48 has also increasingly been
reported since it was ﬁrst isolated in Turkey in 2001 (1–3). While
OXA-48 exhibits low-level hydrolysis of carbapenems, it does not
signiﬁcantly hydrolyze the extended-spectrum cephalosporins,
ceftazidime and cefepime (3, 4). Consistent with in vitro hydroly-
sis data, an in vivo dose ranging study in an immunocompetent
murine peritonitis model resulted in efﬁcacy with ceftazidime
against one ceftazidime-susceptible OXA-48-producing isolate
and poor activity with imipenem, despite the isolate being imi-
penem susceptible (5).
Discordance between in vitro MICs and in vivo efﬁcacy with
humanized regimens of carbapenems has also recently been
demonstrated for KPC- and NDM-1-producing Enterobacteri-
aceae (6, 7). As such, an evaluation of this relationship using hu-
man simulated regimens of carbapenems and comparator agents
forOXA-48 producers in vivo is warranted to assist in determining
the clinical utility of these agents. In order to evaluate the consis-
tency between pharmacodynamic targets and in vivo efﬁcacy of
these agents when used forOXA-48-producing isolates, the in vivo
efﬁcacy of human simulated regimens of doripenem, ertapenem,
ceftazidime, and levoﬂoxacin was characterized against both iso-
genically constructed and clinical OXA-48-producing Enterobac-
teriaceae in a murine thigh infection model.
MATERIALS AND METHODS
Antimicrobial test agents. Commercially available ertapenem (Invanz,
Merck & Co., Inc., Whitehouse Station, NJ), doripenem (Doribax; Jans-
sen Pharmaceuticals, Inc., Raritan, NJ), ceftazidime (Fortaz; GlaxoSmith-
Kline, Philadelphia, PA), and levoﬂoxacin (Sagent Pharmaceuticals,
Schaumburg, IL) were obtained from the pharmacy department at Hart-
ford Hospital. Each antibiotic was reconstituted according to the manu-
facturer’s prescribing information and further diluted in normal saline to
the concentrations required for dosing. Prior to each experiment, dosing
solutions were prepared and stored under refrigeration until the time of
use and were discarded after 24 h.
Bacterial isolates and susceptibility testing. An isogenic pair con-
sisting of a wild-type Klebsiella pneumoniae strain (KP 454) and an
OXA-48 strain derived by conjugation using antibiotic-containing plates,
as well as two clinical OXA-48-producing K. pneumoniae isolates (KP 452
and KP 453), were provided by P. Nordmann, Hospital Bicêtre (Bicêtre,
France). Ertapenem and doripenem MICs for these isolates were deter-
mined via Etest (AB bioMérieux, Solna, Sweden) according to the manu-
facturer’s instructions, while MICs for ceftazidime and levoﬂoxacin were
determined using broth microdilution consistent with the Clinical
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and Laboratory Standards Institute (CLSI) methodology (8). Pseudomo-
nas aeruginosa ATCC 27853 was used as the quality-control strain for
the two agents, with MICs determined by broth microdilution. MIC de-
terminations were conducted in triplicate and are reported as the modal
MIC. Four additional clinical OXA-48-producing Enterobacteriaceae
isolates (KP 464, KP 465, EC 418, CF 32) were kindly provided by C.
Lascols, InternationalHealthManagement Associates, Inc. (Schaumburg,
IL) (9). MICs for these isolates to all four test agents were determined using
brothmicrodilutionasoutlinedabove. Isolateswere screened for thepresence
of KPC, OXA-48-like, VIM, IMP, and NDM carbapenemases, as well as for
extended-spectrum -lactamases (TEM, SHV, and CTX-M) and AmpC
-lactamases (CMY, DHA, FOX, MOX, ACC, and ACT) as previously de-
scribed (9). All isolates were stored in double-strength skim milk (Remel,
Lenexa, KS) at80°C. Prior to all in vivo experiment, each isolate was sub-
cultured twice onto Trypticase soy agar with 5% sheep blood (BD Biosci-
ences, Sparks, MD) and incubated for 18 to 24 h at 35°C.
Immunocompetent thigh infection model. This study was reviewed
and approved by the Institutional Animal Care and Use Committee at
Hartford Hospital, Hartford, CT. Pathogen-free ICR mice weighing 20 to
22 g were acquired from Harlan Laboratories (Indianapolis, IN). All
animals were maintained in accordance with the National Research
Council’s recommendations and were provided food and water ad
libitum. An intraperitoneal injection of uranyl nitrate (5 mg/kg of
body weight) was given 3 days prior to inoculation for each experiment
to slow antibiotic clearance and produce a predictable level of renal
impairment (10). Two hours prior to the initiation of antimicrobial
therapy, both thighs of each animal were inoculated intramuscularly
with 0.1 ml of an inoculum solution containing 108 CFU/ml of the test
isolate in normal saline.
Neutropenic thigh infectionmodel. In order to best characterize the
achievable efﬁcacy of each agent tested, the isogenic pair (wild-type
and OXA-48-producing strains) and three clinical OXA-48-producing
strains were also evaluated in a neutropenic infection model for com-
parison. All mice utilized in the neutropenic studies underwent the
same procedures as described for the immunocompetent model but
were also given intraperitoneal injections of 100 and 150 mg cyclo-
phosphamide/kg (Baxter, Deerﬁeld, IL) 1 and 4 days prior to inocula-
tion, respectively, to induce neutropenia (10). In addition, the inocu-
lum solution used to produce thigh infection in the neutropenic model
was reduced to 107 CFU/ml.
In vivo efﬁcacy. Human-simulated regimens of 2 g doripenem intra-
venously (i.v.) every 8 h as a 4-h infusion, 1 g ertapenem i.v. every 24 h, 2
g ceftazidime i.v. every 8 h as a 2-h infusion, and 500mg levoﬂoxacin every
24 h were previously developed and validated by our group to achieve the
human pharmacodynamic proﬁle associated with each of these dosing
regimens and were utilized throughout the course of the in vivo experi-
ments (11–14). Beginning 2 h after inoculation, groups of threemice were
administered a human simulated regimen of doripenem, ertapenem, cef-
tazidime, or levoﬂoxacin for each test isolate. All doses for the humanized
regimens were administered as 0.2-ml subcutaneous injections; dosing
regimens were repeated as necessary to complete 24 h of therapy. For each
isolate evaluated, groups of three control animals were given normal sa-
line in the same volume, route, and frequency as the most frequently
administered antibiotic regimen over 24 h. One group of untreated con-
trol mice was harvested at 0 h, while the control group receiving normal
saline and all treated mice were harvested at 24 h. Mice that failed to
survive to 24 h were harvested at the time of expiration and were included
in the ﬁnal data analysis. Harvesting consisted of euthanization by CO2
exposure followed by cervical dislocation. Thighs were removed from
sacriﬁced animals, homogenized individually in normal saline, serially
diluted, and plated onto Trypticase soy agar with 5% sheep blood for
determination of bacterial density. Efﬁcacywas calculated as the change in
bacterial density (in log10 CFU) in treatedmice after 24 h from the starting
bacterial densities in 0-h control animals for all experiments conducted in
neutropenicmice. In order to control for the effect of the host and associated
variability in bacterial density of growth controls between isolates in the im-
munocompetent model, efﬁcacy was calculated as the change in bacterial
density in treatedmice after 24 h compared to that in the 24-h immunocom-
petent control mice (6, 15).
RESULTS
Bacterial isolates.A wild-type K. pneumoniae strain (KP 454) and
its derived isogenic OXA-48 strain, in addition to six clinical
OXA-48-producing Enterobacteriaceae isolates, were utilized in
the in vivo experiments. Phenotypic proﬁles for the antimicrobials
evaluated and the known genotypic proﬁles for these isolates are
described in Table 1 (9).
In vivo efﬁcacy. The isogenic wild-type and OXA-48-produc-
ing strains as well as all six clinical OXA-48-producing isolates
were evaluated in the immunocompetent model. The mean
(standard deviation) bacterial density for controlmice at 0 hwas
7.05  0.30 log10 CFU/ml in immunocompetent mice and was
maintained at a mean of 6.41 0.62 log10 CFU/ml after 24 h. The
efﬁcacy results of the immunocompetent studies are shown in Fig.
1. Bacterial reductions1 log CFU were observed with all agents
tested against the wild-type strain. Consistent with phenotypic
proﬁle, ceftazidime and levoﬂoxacin also exhibited efﬁcacy
against the isogenic OXA-48 strain, whereas doripenem did not,
despite having an MIC of 0.38 g/ml; no activity was observed
with ertapenem as anticipated given an MIC of 3 g/ml. Further-
more, 1 log CFU bacterial reductions were also achieved with
the humanized ceftazidime regimen for the two clinical isolates
with MICs of1 g/ml (100% ƒTMIC [time that the free drug
concentration remains above the MIC during the dosing inter-
val]) and one isolate with an MIC of 64 g/ml (0% ƒTMIC);
observed reductions were less for the remaining three clinical
strains, all with MICs of 64 g/ml. The simulated levoﬂoxacin
regimen produced a greater-than-2-log CFU reduction for the
clinical isolate with an MIC of0.03g/ml (area under the curve
[AUC]/MIC 1,467), while little to no efﬁcacywas demonstrated
for the ﬁve isolates with MICs of 4 g/ml (AUC/MIC  11).
Consistent with an MIC of1g/ml (30% ƒTMIC), the sim-
ulated dose of ertapenem did not result in substantial bacterial
reductions for any of the clinical strains. While the observed efﬁ-
cacy for ceftazidime, levoﬂoxacin, and ertapenemagainst the six clin-
ical isolates correlated well with phenotypic proﬁles and pharmaco-
dynamic targets, variable levels of bacterial reductions (range, 0.4 to
TABLE 1 Phenotypic and genotypic proﬁles of wild-type and OXA-48-
producing Enterobacteriaceae isolates utilized in the in vivo efﬁcacy
studies
Isolate
Known -lactamase
content (9)
MIC (g/ml)a
CAZ LEV DOR ETP
K. pneumoniae 454 None 0.25 0.06 0.03 0.012
K. pneumoniae 454 with
OXA-48 plasmid
OXA-48 0.25 0.125 0.38 3
K. pneumoniae 452 OXA-48 0.5 4 3 4
Citrobacter freundii 32 OXA-48, AmpC, CMY 1 0.03 1 1
E. coli 418 OXA-48, CTX-M-15 64 32 2 16
K. pneumoniae 465 OXA-48, CTX-M-15 64 16 2 4
K. pneumoniae 453 OXA-48, CTX-M-15,
TEM-1, OXA-1
128 32 6 2
K. pneumoniae 464 OXA-48, TEM, SHV 128 32 8 64
a DOR, doripenem; ETP, ertapenem; CAZ, ceftazidime; LEV, levoﬂoxacin.
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1.3 log CFU) were noted with the humanized high-dose, prolonged-
infusion doripenem regimen for the six clinical strains with MICs of
8g/ml (ƒTMIC 70%).
In the neutropenic model, the mean bacterial density for con-
trol mice at 0 h was 5.85 0.46 log10 CFU/ml and increased to a
mean of 8.23 0.53 log10 CFU/ml after 24 h. The efﬁcacy results
of the neutropenic studies are shown in Fig. 2. Similar trends in
efﬁcacy with respect to phenotypic proﬁles and pharmacody-
namic targets were noted for ceftazidime, levoﬂoxacin, and ertap-
enem between immunocompetent and neutropenic studies. Efﬁ-
FIG 1 Efﬁcacy of human simulated regimens of 2 g ceftazidime i.v. every 8 h as a 2-h infusion (A), 500 mg levoﬂoxacin i.v. every 24 h (B), 2 g doripenem every
8 h as a 4-h infusion (C), and 1 g ertapenem every 24 h (D) against a distribution of OXA-48-producing Enterobacteriaceae isolates in an immunocompetent
murine thigh infection model. Error bars represent standard deviations. Clinical and Laboratory Standards Institute susceptibility breakpoints: ceftazidime,4
g/ml; levoﬂoxacin,2 g/ml; doripenem,1 g/ml; and ertapenem,0.5 g/ml (8).
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cacy was observed with doripenem against the isogenic and three
clinical OXA-48-producing strains evaluated in the neutropenic
model, all with MICs of 3 g/ml (ƒTMIC of 85% for all
isolates). However, the magnitude of bacterial reduction was
much less than what was observed with doripenem against the
wild-type strain.
DISCUSSION
Carbapenem resistance due to the Ambler class D -lactamase
OXA-48 is increasing among Enterobacteriaceae. Previous work
by our group has demonstrated widely different levels of efﬁca-
cy with carbapenem monotherapy against isolates producing
class A carbapenemases (KPC) versus class B metallo--lactama-
FIG 2 Efﬁcacy of human simulated regimens of 2 g ceftazidime i.v. every 8 h as a 2-h infusion (A), 500 mg levoﬂoxacin i.v. every 24 h (B), 2 g doripenem every
8 h as a 4-h infusion (C), and 1 g ertapenem every 24 h (D) against a distribution of OXA-48-producing Enterobacteriaceae isolates in a neutropenic murine thigh
infection model. Error bars represent standard deviations. Clinical and Laboratory Standards Institute susceptibility breakpoints: ceftazidime, 4 g/ml;
levoﬂoxacin,2 g/ml; doripenem,1 g/ml; and ertapenem,0.5 g/ml (8).
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ses (NDM-1) andoften inconsistentwith previously deﬁnedphar-
macodynamic targets (6, 7). Therefore, it is essential to also char-
acterize the in vivo efﬁcacy of human simulated regimens of
carbapenems for Enterobacteriaceae producing the OXA-48 car-
bapenemase, as each of these enzymes appear to possess various
levels of carbapenem hydrolysis (1, 16). A humanized ceftazidime
regimen was also evaluated in this study, as it has previously dem-
onstrated in vivo efﬁcacy against one OXA-48-producing K. pneu-
moniae isolate in amurine peritonitismodel (5). Levoﬂoxacinwas
included as an additional comparator to provide further valida-
tion of these data, as its pharmacodynamic proﬁle has previously
been well characterized in the murine thigh infection model uti-
lized (4, 17).
The observed efﬁcacy for ceftazidime, levoﬂoxacin, and ertap-
enem against the isogenic and six clinical OXA-48-producing iso-
lates evaluated in both immunocompetent and neutropenic mod-
els correlated well with pharmacodynamic targets and in vitro
MIC. Namely, levoﬂoxacin and ertapenem resulted in very little
activity across the range of clinical isolates, as anticipated based on
a lack of pharmacodynamic target attainment (AUC/MIC 125
and ƒTMIC 40%, respectively) for amajority of isolates tested
(18, 19). Moreover, ceftazidime resulted in reliable efﬁcacy for the
isogenic OXA-48 strain and two of the clinical strains, particularly
when MICs were 1 g/ml, corresponding to 100% ƒTMIC.
The preservation of good in vitro susceptibility and in vivo efﬁcacy
among these isolates is consistent with previously published in
vitro hydrolysis data for the OXA-48 enzyme, demonstrating
very little hydrolysis of extended-spectrum cephalosporins (3, 4).
Much less efﬁcacy was noted with ceftazidime against the four
isolates with elevated MICs (64 g/ml, 0% ƒTMIC), second-
ary to the coproduction of extended-spectrum beta-lactamases
(ESBLs). Nonetheless, the level of ceftazidime efﬁcacy observed
was fairly consistent with phenotypic and pharmacodynamic
proﬁles across the isolates evaluated. These ﬁndings are also sup-
ported by two case reports in which susceptible OXA-48-produc-
ing Enterobacteriaceae were successfully treated with expanded-
spectrum cephalosporins. A case of neonatal pneumonia caused
by an OXA-48-producing K. pneumoniae isolate susceptible to
ceftazidime and cefotaxime was successfully treated with a com-
bination of cefotaxime and amikacin (20). Another patient with
leukemia who developed a central line infection caused by an
OXA-48-producing Escherichia coli strain, susceptible to all ceph-
alosporins, successfully cleared their infectionwith a combination
of ceftazidime and colistin (17). While ceftazidime may be a
promising option for susceptible OXA-48 producers, there are
still a large proportion of OXA-48-producing Enterobacteriaceae
that coproduce other extended-spectrum beta-lactamases. A re-
cent surveillance study that included 107 OXA-48-producing En-
terobacteriaceae from European and North African countries
found that 75%of these isolates coproduced ESBLs, withCTX-M-
like enzymes being the most predominant, accounting for 89% of
ESBL enzymes (21). Furthermore, 58.9%of these ESBL andOXA-
48-coproducing isolates displayed in vitro resistance to ceftazi-
dime.Consequently, ceftazidimemay be a viable treatment option
for OXA-48-producing Enterobacteriaceae, but only when in vitro
susceptibility is demonstrated, as genotypic data are often not
available in clinical settings.
High-dose, prolonged-infusion doripenemdisplayed somede-
gree of efﬁcacy against the isogenic and clinical strains tested in
both models; however, the magnitude of bacterial reduction ap-
peared to be much less than that of the wild-type strain. Further-
more, the level of efﬁcacy was not consistent across the entire
range of isolates, despite having achieved the required pharmaco-
dynamic target of40% ƒTMIC (18). Our data demonstrating
variable activity with this regimen appear to be consistent with
prior in vivo and clinical observations. In a previous dose ranging
study, ceftazidime demonstrated activity against a single suscep-
tible OXA-48-producing strain, while imipenem lacked in vivo
efﬁcacy against this same isolate despite being imipenem sus-
ceptible. Furthermore, a number of case reports and case series
describe treatment failures with imipenem- or meropenem-
containing regimens when treating infections caused by OXA-
48-producing Enterobacteriaceae (22–24). While the in vitro hy-
drolysis proﬁle of doripenem with OXA-48 does not appear to
have been evaluated to date, it is not entirely surprising that activ-
ity was still observed against some isolates evaluated in the current
study, as there appears to be a difference in the level of hydrolysis
among agents within the carbapenem class. In two separate en-
zyme kinetic studies of OXA-48, hydrolytic activity was much
greater for imipenem than for meropenem and ertapenem in one
study (3, 4). Since doripenem monotherapy was not as reliable as
anticipated based on the phenotypic proﬁle of the organisms in-
cluded, future evaluations of carbapenem-based combination
therapy regimens are warranted.
The in vivo activity observed with ceftazidime, levoﬂoxacin,
and ertapenem against the isogenic and clinical OXA-48-produc-
ing strains correlated well with pharmacodynamic targets and in
vitro MIC. While levoﬂoxacin and ertapenem did not result in
efﬁcacy against a majority of the strains evaluated as predicted
based on elevated MICs, ceftazidime may represent a viable treat-
ment option for OXA-48-producing Enterobacteriaceae when cef-
tazidime susceptible. Similar to previous in vivo and clinical
observations of carbapenem failure against susceptible OXA-48-
producing Enterobacteriaceae, activity with high-dose, prolonged-
infusion doripenem was not consistent over the MIC range stud-
ied, despite this regimen achieving the requisite ƒTMIC needed
for efﬁcacy against all isolates. These data add to previous obser-
vations against KPC- and NDM-1-producing organisms suggest-
ing that genotype may better predict carbapenem activity than the
phenotypic proﬁle for carbapenem-resistant Enterobacteriaceae.
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